Too many red flags for them to touch due to:
- No IP moat (key patents are expired with more key patents due to expire in 2022 and 2024) - they've already had a copycat competitor emerge which they've tried to sue and failed.
- High cash burn rate
- They find the claim of a huge market bizzare given the rate of sales growth does not match the cash burn rate and long path to just break even
- Not shareholder friendly - dilutive capital raisings favouring instos
- Excessive management remuneration before they've achieved anything worth justifying it
- Given the above issues the valuation is far to excessive for them to even consider.
- Forums
- ASX - By Stock
- AVH
- AVH on NASDAQ
AVH on NASDAQ, page-929
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.76 |
Change
0.130(4.94%) |
Mkt cap ! $187.9M |
Open | High | Low | Value | Volume |
$2.74 | $2.77 | $2.66 | $1.044M | 382.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 980 | $2.74 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.76 | 10173 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 980 | 2.740 |
3 | 36189 | 2.700 |
1 | 10000 | 2.680 |
3 | 2022 | 2.630 |
1 | 2671 | 2.620 |
Price($) | Vol. | No. |
---|---|---|
2.760 | 10173 | 2 |
2.770 | 17029 | 3 |
2.780 | 1500 | 1 |
2.790 | 3162 | 1 |
2.800 | 2372 | 3 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online